Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

84.43 -0.05

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

84.4

Massimo

84.7

Metriche Chiave

By Trading Economics

Entrata

7M

-121M

Vendite

14M

25M

EPS

-1.14

Margine di Profitto

-481.149

Dipendenti

594

EBITDA

-4.7M

-131M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+1.3% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

63M

8.9B

Apertura precedente

84.48

Chiusura precedente

84.43

Notizie sul Sentiment di mercato

By Acuity

60%

40%

292 / 340 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 ago 2026, 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

13 ago 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

13 ago 2026, 23:51 UTC

News

Milestone Scientific reported second-quarter sales of $2.841 million, exceeding estimates. Shares are higher in after-market hours following the earnings announcement.

13 ago 2026, 23:51 UTC

News
Social Media

Campbell Soup Co filed for a mixed securities shelf to raise capital. Shares are higher in after-market trading amid positive social media sentiment.

13 ago 2026, 23:51 UTC

News
Social Media

Charter Communications received final approval for its Cox acquisition, but shares are trading lower in after-market hours, reflecting downward pressure since Thursday's close.

13 ago 2026, 23:46 UTC

News

Citi analyst Ronald Josey raised Wayfair's price target to $133.00 from $95.00, maintaining a Buy rating. Shares are trading higher in after-market hours.

13 ago 2026, 23:46 UTC

News
Correlated Moves

Synchrony Financial shares declined in after-market hours following the appointment of Nimrod Barak as Chief AI Officer, effective June 30, 2026.

13 ago 2026, 23:46 UTC

News

UWM Holdings Corp secures $2.05 billion investment from Oaktree and SFS Group. Shares are trading higher in after-market hours following the announcement.

13 ago 2026, 23:41 UTC

News

EPR Properties declared a monthly cash dividend of $0.31 per share, payable September 15, 2026, as shares moved higher during after-market hours.

13 ago 2026, 23:41 UTC

News

Credicorp Ltd reported second-quarter earnings of $7.29 per share, exceeding estimates. The stock moved higher during after-market hours following this performance.

13 ago 2026, 23:41 UTC

Social Media
News

Eton Pharmaceuticals reported record revenue of $37.6 million and raised its full-year guidance to over $145 million, driving shares higher in after-market trading.

13 ago 2026, 23:41 UTC

News

Norway's sovereign wealth fund increased its Bitcoin exposure through MicroStrategy investments. Bitcoin is trading lower today, remaining below its 20-day moving average.

13 ago 2026, 23:36 UTC

News

Lucid Group Inc introduced the Lucid Gravity GT-S SUV priced at $125,900, but shares declined in after-market trading following the announcement.

13 ago 2026, 23:31 UTC

News

Western Union shares rise in after-market trading following New York Governor Kathy Hochul's approval of its acquisition of International Money Express.

13 ago 2026, 23:31 UTC

Correlated Moves
News
Social Media

Microsoft shares are trading lower after a report on OpenAI's $40 billion revenue run rate and Iren's $9.7 billion cloud services contract.

13 ago 2026, 23:31 UTC

Social Media
News

Micron Technology launches a $250 million AI-focused fund, raising total commitments to $550 million. Shares are trading higher in after-market hours.

13 ago 2026, 23:31 UTC

News
Social Media

Nu Holdings Ltd shares rose in after-market trading following strong Q2 results, with revenue of $5.9 billion surpassing estimates and net profit reaching $1.06 billion.

13 ago 2026, 23:26 UTC

News

CoreCivic Inc shares rose in after-market trading following positive analyst ratings updates and a raised price target from Benchmark Co. to $45.00.

13 ago 2026, 23:26 UTC

Correlated Moves
News

Diodes Inc announced a $325 million private placement of convertible senior notes due 2031. Shares are lower in after-market trading amid broader market trends.

13 ago 2026, 23:26 UTC

News

Hewlett Packard Enterprise shares rose in after-market trading, buoyed by positive sentiment from Cisco's earnings and broader market gains.

13 ago 2026, 23:21 UTC

News

Knight-Swift Transportation affirms quarterly cash dividend of $0.20 per share, though shares are trading lower in after-market hours.

13 ago 2026, 23:21 UTC

News

Rapid7 Inc shares rose in after-market trading after reporting adjusted EPS of $0.44, exceeding expectations, and raising full-year guidance to $1.81.

13 ago 2026, 23:16 UTC

News
Correlated Moves

Citigroup's U.S. Consumer Cards business will acquire Kard Financial to enhance credit card rewards for its 70 million cardmembers. Shares are little changed in after-market trading.

13 ago 2026, 23:16 UTC

Correlated Moves
News

Sunrun Inc. shares declined in after-market trading, reflecting broader market trends. Recent financial results showed sales of $543.73 million and revenue of $869.99 million.

13 ago 2026, 23:16 UTC

News

Jack in the Box Inc shares rose in after-market trading following UBS and Citigroup raising their price targets to $20, indicating a stable outlook.

13 ago 2026, 23:11 UTC

News

Sabre Corp reported second-quarter revenue of $712 million and raised its full-year profitability outlook, though shares are trading lower in after-market hours.

13 ago 2026, 23:06 UTC

Social Media
News

Tesla shares gained in after-market hours following the end of a lengthy strike by IF Metall and as Michael Burry covered his short position.

13 ago 2026, 23:06 UTC

News

Silicon Motion Technology closed a $1.15 billion offering of Convertible Senior Notes due 2031, with shares trading higher in after-market hours.

13 ago 2026, 23:06 UTC

News
Event

Target Corp will announce Q2 FY2026 earnings on August 19, with an estimated EPS of $2.24 and revenue of $25.7 billion. Shares showed little change after hours.

13 ago 2026, 23:02 UTC

Social Media
News

Cboe Global Markets announced a dividend increase to $0.86 per share, effective September 15, 2026. Shares are trading higher in after-market hours.

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.3% in crescita

Previsioni per 12 mesi

Media 85.56 USD  1.3%

Alto 95 USD

Basso 80 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

2

Acquista

12

Mantieni

0

Vendi

Sentiment

By Acuity

292 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat